Advanced Strategies for Constructing Self‐Assembled Peptide Hydrogels/Nanoparticles for Cancer Treatment
Source abstract
Abstract
Abstract Peptide hydrogels are of their well‐suited porous structure, high biocompatibility, ease of penetration, and facile functionalization. In this review, several triggering methods are summarized for producing anticancer peptide‐based nanofibers, nanohydrogels, and nanoparticles (NPs), employing various factors such as heating‐cooling, solvent‐switch method, ionic strength, concentration, sonication, hydrogen ion concentration (pH), photo‐crosslinking, and liquid–liquid phase separation (LLPS) methods. Both linear and cyclic peptides can be incorporated into self‐assembled nanofibers, nanoparticles, and nanohydrogels, and/or their structures may be used alternatively under specific circumstances. Furthermore, as a mild, residue‐free approach that does not disrupt the hydrogel structure, supercritical carbon dioxide (sc‐CO 2 ) can also be incorporated to solve the challenging problems of hydrogel sterilization.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Chemical Synthesis and Analysis · Polydiacetylene-based materials and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Vaccines for Infectious Diseases Xiang'an Biomedicine Laboratory Fujian Engineering Research Center of Molecular Theranostic Technology Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen 361102 China
Department of Pharmacy Xiamen Medical College Xiamen 361008 China
Institute of Industrial Biotechnology Government College University Lahore Punjab 54000 Pakistan
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Fujian Provincial Health Technology Project · Major State Basic Research Development Program of China
References (100+)
Show source-provided references
1. 10.1158/2159-8290.CD-21-105910.1158/2159-8290.CD-21-1059 ↗
2. 10.3322/caac.2183410.3322/caac.21834 ↗
3. 10.1038/s41571-024-00948-110.1038/s41571-024-00948-1 ↗
4. Baba Y. · MITAT · 2018 · 27 · 17
5. Forbes J. · Biochem. Pept. · 2020 · 8 · 5931
6. 10.3390/cancers1605103210.3390/cancers16051032 ↗
7. 10.1111/ijfs.1404810.1111/ijfs.14048 ↗
8. 10.1038/s41392-022-00904-410.1038/s41392-022-00904-4 ↗
9. 10.1007/978-981-19-8249-1_110.1007/978-981-19-8249-1_1 ↗
10. Kota S. · 2019
11. 10.1039/D4NA00172A10.1039/D4NA00172A ↗
12. 10.1021/acsami.9b1215210.1021/acsami.9b12152 ↗
13. 10.1002/adhm.20200123910.1002/adhm.202001239 ↗
14. 10.1016/j.bioadv.2023.21367310.1016/j.bioadv.2023.213673 ↗
15. 10.1007/s10930-024-10200-510.1007/s10930-024-10200-5 ↗
16. 10.1063/5.014230210.1063/5.0142302 ↗
17. 10.1039/C6RA21261A10.1039/C6RA21261A ↗
18. Khedr A. · 2023 · 1
19. Administration U. S. F. a. D. Abraxane Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf(accessed: December 2024).
20. 10.1073/pnas.173060910010.1073/pnas.1730609100 ↗
21. 10.1039/D0RA06237E10.1039/D0RA06237E ↗
22. 10.1517/13543784.16.11.185110.1517/13543784.16.11.1851 ↗
23. 10.2147/IJN.S40104810.2147/IJN.S401048 ↗
24. Zhu Z. · bioRxiv · 2025 · 03
25. 10.1126/sciadv.adv197110.1126/sciadv.adv1971 ↗
26. 10.1039/C6CS00176A10.1039/C6CS00176A ↗
27. 10.1021/accountsmr.4c0039110.1021/accountsmr.4c00391 ↗
28. Samdin T. D. · 2025
29. 10.1021/acsabm.5c0019910.1021/acsabm.5c00199 ↗
30. 10.1038/s41565-024-01654-w10.1038/s41565-024-01654-w ↗
31. 10.1021/ct200757a10.1021/ct200757a ↗
32. 10.3390/gels1103016410.3390/gels11030164 ↗
33. 10.1038/s41563-023-01648-410.1038/s41563-023-01648-4 ↗
34. 10.1016/j.chempr.2023.05.00910.1016/j.chempr.2023.05.009 ↗
35. 10.1021/acs.accounts.3c0059210.1021/acs.accounts.3c00592 ↗
36. 10.1021/acs.jpcb.7b0308510.1021/acs.jpcb.7b03085 ↗
37. 10.1021/acs.langmuir.3c0342610.1021/acs.langmuir.3c03426 ↗
38. 10.1063/5.022630010.1063/5.0226300 ↗
39. 10.1016/j.foodhyd.2024.11099110.1016/j.foodhyd.2024.110991 ↗
40. 10.3390/pharmaceutics1411253310.3390/pharmaceutics14112533 ↗
41. 10.1021/acs.molpharmaceut.8b0083610.1021/acs.molpharmaceut.8b00836 ↗
42. 10.1002/adma.20231292010.1002/adma.202312920 ↗
43. 10.1021/acs.langmuir.6b0105910.1021/acs.langmuir.6b01059 ↗
44. 10.3390/pharmaceutics1503102610.3390/pharmaceutics15031026 ↗
45. 10.1021/acsnano.2c0140710.1021/acsnano.2c01407 ↗
46. 10.1021/jacs.2c0102510.1021/jacs.2c01025 ↗
47. 10.1002/jbm.a.3605910.1002/jbm.a.36059 ↗
48. 10.1016/j.chempr.2023.10.00510.1016/j.chempr.2023.10.005 ↗
49. 10.1038/s41419-022-04639-610.1038/s41419-022-04639-6 ↗
50. 10.1039/D2TB00917J10.1039/D2TB00917J ↗
51. 10.1002/adma.20210470410.1002/adma.202104704 ↗
52. 10.1016/j.matt.2023.03.02910.1016/j.matt.2023.03.029 ↗
53. 10.1021/acs.biomac.4c0083610.1021/acs.biomac.4c00836 ↗
54. 10.1039/D0BM00134A10.1039/D0BM00134A ↗
55. 10.1016/j.actbio.2022.11.00810.1016/j.actbio.2022.11.008 ↗
56. 10.1016/j.actbio.2020.12.05210.1016/j.actbio.2020.12.052 ↗
57. 10.1039/C9NR08916K10.1039/C9NR08916K ↗
58. 10.1039/D0NR08741F10.1039/D0NR08741F ↗
59. 10.1007/s00299-003-0708-410.1007/s00299-003-0708-4 ↗
60. 10.1016/j.nantod.2021.10119810.1016/j.nantod.2021.101198 ↗
61. 10.1002/adma.20180152710.1002/adma.201801527 ↗
62. Su L. · Oncol Rep · 2010 · 23 · 3
63. 10.1080/00914037.2020.186713410.1080/00914037.2020.1867134 ↗
64. 10.1021/acs.langmuir.9b0371810.1021/acs.langmuir.9b03718 ↗
65. 10.1021/acs.biomac.4c0079510.1021/acs.biomac.4c00795 ↗
66. 10.1021/acsanm.3c0581510.1021/acsanm.3c05815 ↗
67. 10.1002/anie.20140221610.1002/anie.201402216 ↗
68. 10.1002/adtp.20190001010.1002/adtp.201900010 ↗
69. 10.1016/j.cej.2024.15247910.1016/j.cej.2024.152479 ↗
70. 10.1016/j.bioactmat.2021.12.03310.1016/j.bioactmat.2021.12.033 ↗
71. 10.1002/adma.20200331010.1002/adma.202003310 ↗
72. 10.1039/D3SM01057K10.1039/D3SM01057K ↗
73. 10.1016/j.bioactmat.2021.03.04110.1016/j.bioactmat.2021.03.041 ↗
74. 10.1002/adma.20200851810.1002/adma.202008518 ↗
75. 10.1002/adfm.20231477210.1002/adfm.202314772 ↗
76. 10.1002/anie.20191511810.1002/anie.201915118 ↗
77. 10.1007/s11595-013-0741-210.1007/s11595-013-0741-2 ↗
78. 10.1021/acs.biomac.7b0078710.1021/acs.biomac.7b00787 ↗
79. 10.1021/acs.jpclett.2c0117110.1021/acs.jpclett.2c01171 ↗
80. 10.1021/acs.biomac.1c0026710.1021/acs.biomac.1c00267 ↗
81. 10.1002/anie.20191178210.1002/anie.201911782 ↗
82. 10.31635/ccschem.023.20230299010.31635/ccschem.023.202302990 ↗
83. 10.1016/j.biomaterials.2023.12245110.1016/j.biomaterials.2023.122451 ↗
84. 10.1021/acsbiomaterials.6b0007610.1021/acsbiomaterials.6b00076 ↗
85. Empting M. · 2017
86. 10.1002/psc.340310.1002/psc.3403 ↗
87. 10.1021/acsnano.0c0328610.1021/acsnano.0c03286 ↗
88. 10.3390/polym1421455410.3390/polym14214554 ↗
89. 10.1016/j.intimp.2024.11319510.1016/j.intimp.2024.113195 ↗
90. 10.1002/adfm.20190496910.1002/adfm.201904969 ↗
91. 10.1039/C8NH00009C10.1039/C8NH00009C ↗
92. 10.1039/D2TB01721K10.1039/D2TB01721K ↗
93. 10.1002/chem.20180457610.1002/chem.201804576 ↗
94. 10.1016/j.nantod.2024.10224710.1016/j.nantod.2024.102247 ↗
95. 10.1016/j.colsurfa.2019.04.02010.1016/j.colsurfa.2019.04.020 ↗
96. 10.1016/j.crhy.2017.05.00310.1016/j.crhy.2017.05.003 ↗
97. 10.1038/s41565-024-01766-310.1038/s41565-024-01766-3 ↗
98. 10.1016/j.ijpharm.2023.12267110.1016/j.ijpharm.2023.122671 ↗
99. 10.3390/gels1102011410.3390/gels11020114 ↗
100. 10.1088/1742-6596/2961/1/01202110.1088/1742-6596/2961/1/012021 ↗